To develop and optimize the world’s leading health and wellness ecosystem.
Mountain Valley MD is building a world-class health and wellness organization centred around the implementation of its patented Quicksome™ oral drug formulation and delivery technologies to innovate industry leading products that are sought out globally.
MVMD’s proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ technology to its ground-breaking work for the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.
The Company’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy.
We are working with advanced desiccated liposome formulations and the related international patents for advanced compressible delivery formulations for transmucosal delivery. Our proposition for delivering formulations that have rapid onset, with high bioavailability, with precision dosing technology will be core to our success across leading health and wellness application categories.
Ease of Delivery
Precision Dosing Technology
“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”
“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”
“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”
“We believe Mountain Valley MD’s patented Quicksome™ technology revolutionizes drug and nutraceutical ingredient delivery for superior health outcomes by simultaneously addressing a multitude of key drug and nutraceutical product efficacy challenges, such as low bioavailability, high absorption variability and poor dosage control.”
“Many of the active ingredients contained in traditional pharmaceutical drugs and nutraceutical supplements are not well absorbed and suffer extensive degradation during first pass metabolism. We feel this is exactly the problem that Mountain Valley MD’s direct-to-mouth Quicksome™ technology solves, dramatically improving bioavailability of compounds that are traditionally heavily metabolized by MAO enzymes, glucuronidation and other conjugation processes”.
“We have an amazingly talented team that is working on solving some very advanced challenges in the health and wellness space. To date we have done research and development work with more than 60 molecules for a variety of nutraceutical and pharmaceutical applications, including drugs, vaccines, the emerging mushroom space and cannabinoids.”
“For me personally, the idea that our delivery technology could help dispense drugs such as insulin or deliver vaccines into the body through a rapid dissolve sublingual strip and eliminate the need for painful needle injections is truly game changing.”